Cargando…
The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025489/ https://www.ncbi.nlm.nih.gov/pubmed/29848986 http://dx.doi.org/10.3390/cancers10060169 |
_version_ | 1783336291548528640 |
---|---|
author | M’kacher, Radhia Cuceu, Corina Al Jawhari, Mustafa Morat, Luc Frenzel, Monika Shim, Grace Lenain, Aude Hempel, William M. Junker, Steffen Girinsky, Theodore Colicchio, Bruno Dieterlen, Alain Heidingsfelder, Leonhard Borie, Claire Oudrhiri, Noufissa Bennaceur-Griscelli, Annelise Moralès, Olivier Renaud, Sarah Van de Wyngaert, Zoé Jeandidier, Eric Delhem, Nadira Carde, Patrice |
author_facet | M’kacher, Radhia Cuceu, Corina Al Jawhari, Mustafa Morat, Luc Frenzel, Monika Shim, Grace Lenain, Aude Hempel, William M. Junker, Steffen Girinsky, Theodore Colicchio, Bruno Dieterlen, Alain Heidingsfelder, Leonhard Borie, Claire Oudrhiri, Noufissa Bennaceur-Griscelli, Annelise Moralès, Olivier Renaud, Sarah Van de Wyngaert, Zoé Jeandidier, Eric Delhem, Nadira Carde, Patrice |
author_sort | M’kacher, Radhia |
collection | PubMed |
description | Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were included in this study. Seven HL cell lines were used as in vitro models. Telomerase activity (TA) was assessed by TRAP assay and verified through hTERT immunofluorescence expression; alternative telomere lengthening (ALT) was also assessed, along with EBV status. Results: Both TA and ALT mechanisms were present in HL lymph nodes. Our findings were reproduced in HL cell lines. The highest levels of TA were expressed in CD30−/CD15− cells. Small cells were identified with ALT and TA. Hodgkin and Reed Sternberg cells contained high levels of PML bodies, but had very low hTERT expression. There was a significant correlation between overall survival (p < 10(−3)), event-free survival (p < 10(−4)), and freedom from progression (p < 10(−3)) and the presence of an ALT profile in lymph nodes of EBV+ patients. Conclusion: The presence of both types of TMMs in HL lymph nodes and in HL cell lines has not previously been reported. TMMs correlate with the treatment outcome of EBV+ HL patients. |
format | Online Article Text |
id | pubmed-6025489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60254892018-07-09 The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes M’kacher, Radhia Cuceu, Corina Al Jawhari, Mustafa Morat, Luc Frenzel, Monika Shim, Grace Lenain, Aude Hempel, William M. Junker, Steffen Girinsky, Theodore Colicchio, Bruno Dieterlen, Alain Heidingsfelder, Leonhard Borie, Claire Oudrhiri, Noufissa Bennaceur-Griscelli, Annelise Moralès, Olivier Renaud, Sarah Van de Wyngaert, Zoé Jeandidier, Eric Delhem, Nadira Carde, Patrice Cancers (Basel) Article Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were included in this study. Seven HL cell lines were used as in vitro models. Telomerase activity (TA) was assessed by TRAP assay and verified through hTERT immunofluorescence expression; alternative telomere lengthening (ALT) was also assessed, along with EBV status. Results: Both TA and ALT mechanisms were present in HL lymph nodes. Our findings were reproduced in HL cell lines. The highest levels of TA were expressed in CD30−/CD15− cells. Small cells were identified with ALT and TA. Hodgkin and Reed Sternberg cells contained high levels of PML bodies, but had very low hTERT expression. There was a significant correlation between overall survival (p < 10(−3)), event-free survival (p < 10(−4)), and freedom from progression (p < 10(−3)) and the presence of an ALT profile in lymph nodes of EBV+ patients. Conclusion: The presence of both types of TMMs in HL lymph nodes and in HL cell lines has not previously been reported. TMMs correlate with the treatment outcome of EBV+ HL patients. MDPI 2018-05-30 /pmc/articles/PMC6025489/ /pubmed/29848986 http://dx.doi.org/10.3390/cancers10060169 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article M’kacher, Radhia Cuceu, Corina Al Jawhari, Mustafa Morat, Luc Frenzel, Monika Shim, Grace Lenain, Aude Hempel, William M. Junker, Steffen Girinsky, Theodore Colicchio, Bruno Dieterlen, Alain Heidingsfelder, Leonhard Borie, Claire Oudrhiri, Noufissa Bennaceur-Griscelli, Annelise Moralès, Olivier Renaud, Sarah Van de Wyngaert, Zoé Jeandidier, Eric Delhem, Nadira Carde, Patrice The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes |
title | The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes |
title_full | The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes |
title_fullStr | The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes |
title_full_unstemmed | The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes |
title_short | The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes |
title_sort | transition between telomerase and alt mechanisms in hodgkin lymphoma and its predictive value in clinical outcomes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025489/ https://www.ncbi.nlm.nih.gov/pubmed/29848986 http://dx.doi.org/10.3390/cancers10060169 |
work_keys_str_mv | AT mkacherradhia thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT cuceucorina thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT aljawharimustafa thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT moratluc thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT frenzelmonika thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT shimgrace thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT lenainaude thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT hempelwilliamm thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT junkersteffen thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT girinskytheodore thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT colicchiobruno thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT dieterlenalain thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT heidingsfelderleonhard thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT borieclaire thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT oudrhirinoufissa thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT bennaceurgriscelliannelise thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT moralesolivier thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT renaudsarah thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT vandewyngaertzoe thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT jeandidiereric thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT delhemnadira thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT cardepatrice thetransitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT mkacherradhia transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT cuceucorina transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT aljawharimustafa transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT moratluc transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT frenzelmonika transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT shimgrace transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT lenainaude transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT hempelwilliamm transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT junkersteffen transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT girinskytheodore transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT colicchiobruno transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT dieterlenalain transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT heidingsfelderleonhard transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT borieclaire transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT oudrhirinoufissa transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT bennaceurgriscelliannelise transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT moralesolivier transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT renaudsarah transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT vandewyngaertzoe transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT jeandidiereric transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT delhemnadira transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes AT cardepatrice transitionbetweentelomeraseandaltmechanismsinhodgkinlymphomaanditspredictivevalueinclinicaloutcomes |